Overview

Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas

Status:
Recruiting

Trial end date:
2024-04-30

Target enrollment:

Participant gender:

Summary

This trial aims to study the performance of Elucirem® (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas.

Phase:

Phase 3

Details

Lead Sponsor:

Guerbet

Treatments:

Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate